A rash diagnosis: Gemcitabine-associated pseudocellulitis

Area of Science:

• Oncology
• Dermatology
• Clinical Pharmacology

Background:

• Gemcitabine is a widely used chemotherapy drug.
• Cutaneous toxicities, including rash and pruritus, are common side effects.
• A severe 'pseudocellulitis' rash, mimicking infectious cellulitis, is a recognized rare complication.

Purpose of the Study:

• To report a case of biopsy-confirmed gemcitabine-associated pseudocellulitis.
• To highlight the clinical presentation and management of this rare adverse event.
• To emphasize the importance of recognizing this complication to prevent unnecessary interventions.

Main Methods:

• Case report of a patient with metastatic pancreatic adenocarcinoma treated with gemcitabine.
• Clinical observation of a severe rash resembling cellulitis.
• Biopsy confirmation of the pseudocellulitis reaction.
• Review of literature regarding gemcitabine-induced pseudocellulitis.

Main Results:

• The patient developed a severe rash consistent with pseudocellulitis after gemcitabine administration.
• The reaction was biopsy-confirmed and occurred in the context of lymphadenopathy.
• The rash was self-limiting, resolving within days without specific treatment.
• Gemcitabine treatment was continued safely, despite the recurrence of the rash upon subsequent doses.

Conclusions:

• Gemcitabine-associated pseudocellulitis is a rare but important dermatologic complication.
• Prompt recognition can prevent misdiagnosis as infectious cellulitis, avoiding unnecessary antibiotics and hospitalization.
• This condition is typically self-limiting, and gemcitabine therapy can often be safely continued.